Revised myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia

Revised myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia

Myeloproliferative neoplasms (MPNs) are clonal disorders, derived from abnormal hematopoietic stem cells and result in an excessive production of blood cells. This MPN group of conditions encompasses different diseases with overlapping clinical and biologic similarities. The majority of the conventi...

Full description

Saved in:
Bibliographic Details
Main Authors: Mohan B Agarwal, Hemant Malhotra, Prantar Chakarborti, Neelam Varma, Vikram Mathews, Jina Bhattacharyya, Tulika Seth, K Gyathri, Hari Menon, P G Subramanian, Ajay K Sharma, Maitreyee Bhattacharyya, Jay Mehta, Sandeep Shah, P K Gogoi, Reena Nair, Usha Agarwal, Subhash Varma, SVVS Prasad, Deepak K Mishra
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2018-01-01
Series:Indian Journal of Medical and Paediatric Oncology
Subjects:
Essential thrombocythemia Janus kinase
myelofibrosis
myeloproliferative neoplasm
polycythemia vera
Online Access:http://www.ijmpo.org/article.asp?issn=0971-5851;year=2018;volume=39;issue=4;spage=503;epage=515;aulast=Agarwal
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Myeloproliferative neoplasms (MPNs) are clonal disorders, derived from abnormal hematopoietic stem cells and result in an excessive production of blood cells. This MPN group of conditions encompasses different diseases with overlapping clinical and biologic similarities. The majority of the conventional therapies of MPN are palliative in nature. However, with the discovery of Janus Kinase 2 (JAK2) mutation and development of targeted JAK1/2 inhibition therapy, the therapeutic options in treatment landscape have changed dramatically. This article presents the revised Indian MPNs Working Group consensus recommendations. It highlights and brings into attention about the recent findings that have defined the state of the art of the diagnosis and therapy in the MPN area, including identification of the new driver and prognostic mutations, treatment goals in the management of myelofibrosis and polycythemia vera (PV), role of the recently approved, targeted tyrosine kinase inhibitor ruxolitinib in PV, and special issues such MPN consideration in patients with splenic vein thrombosis and the management of the disease in pregnancy.
ISSN:0971-5851

Similar Items